RxDoctor Payments Data

Mark Callow, MD

Neurology · West Chester, OHNPI 1457644338

Payments from drug & device makers

$35,549in general payments, 2019–2025

Across 420 payments — averaging $84.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$17K
  • Sunovion Pharmaceuticals Inc.$7K
  • Livanova USA, Inc.$4K
  • Catalyst Pharmaceuticals, Inc.$2K
  • SK Life Science, Inc.$2K
  • Supernus Pharmaceuticals, Inc.$703
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$7202%
  • Speaking & faculty fees$26,11573%
  • Travel & lodging$1,0033%
  • Food & beverage$7,71122%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,549 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$55,854
Medicare patients
296
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)128$740,660
BriviactBrivaracetam180$332,963
FinteplaFenfluramine Hcl14$188,212
XcopriCenobamate148$177,337
AptiomEslicarbazepine Acetate62$140,288
NayzilamMidazolam141$138,827
FycompaPerampanel102$112,222
Oxtellar XrOxcarbazepine28$91,808
Clobazam371$87,671
Lamictal XrLamotrigine17$75,478
Topiramate ErTopiramate75$63,363
LamictalLamotrigine32$63,265
Lamotrigine ErLamotrigine133$59,083
VimpatLacosamide23$52,707
Keppra XrLevetiracetam15$43,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Fintepla, Nayzilam, Vimpat$17,460$712,708358 claims
SK Life Science, Inc.Xcopri$1,593$177,337148 claims
Sunovion Pharmaceuticals Inc.Aptiom$7,282$140,28862 claims
Eisai Inc.Fycompa$552$112,222102 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$703$91,80828 claims
Neurelis, Inc.Valtoco$502$38,02512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.

Other neurology in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →